HoFH Drug Juxtapid No Longer Available in EU

Post Date: 
21 July 2016

Aegerion has announced they will no longer market Juxtapid (lomitapide) in Europe for the treatment of homozygous familial hypercholesterolemia (HoFH). 
 Just a couple years ago, the drug was deemed one of the most expensive orphan drugs on the market ($300K per year) but its market share has likely plummeted due to the approvals of Kynamro in 2014 to treat HoFH and the less expensive Repatha (evolocumab) in 2015 that treats both the homozygous (ultra rare) and heterozygous (very common) versions of FH.